Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023
100% overall response rate and 70% complete response rate observed in standard of care relapsed/refractory AL Amyloidosis patients with median 6 lines of prior therapy in updated Phase...
Source: marketscreener.com